new-recommended-broker-banner new-recommended-broker-banner

EyeGate Pharma Stock Surges After Panoptes Pharma Acquisition

Updated: 21 Dec 2020

Shares of EyeGate Pharmaceuticals (NASDAQ: EYEG) are rallying premarket on Monday after the company revealed it will acquire Panoptes Pharma, a privately-held clinical-stage biotech company.

EyeGate said the acquisition will transform its pipeline with the addition of PP-001, a “next-generation, non-steroidal, immuno-modulatory, small-molecule inhibitor of Dihydroorotate Dehydrogenase (DHODH) with potential best-in-class picomolar potency.”

EyeGate will pay $4 million for Panoptes, which will consist of EyeGate common stock, preferred stock and cash. A further $1.5 million in EyeGate common stock will be issued after 18 months, subject to certain conditions.

The transaction also includes two cash or share earn-out provisions, each for an additional payment of up to $4,750,000 contingent upon 1) the enrollment and randomisation of a first patient into the first Phase III pivotal study of any Panoptes ophthalmic product with the FDA, and 2) approval of a New Drug Application by the FDA for any Panoptes ophthalmic product.

“The acquisition of Panoptes propels the EyeGate pipeline forward to include a de-risked clinical-stage candidate with broad potential across a diverse range of ocular, autoimmune and neurological indications,” said Stephen From, CEO of EyeGate.

The news has resulted in a rally for EyeGate’s share price. It is currently up 85.87% premarket at $6.60 following Friday's close at $3.57.

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage . 75 % of retail investor accounts lose money when trading CFDs with this provider . You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money .